JP Morgan Chase’s Adial Pharmaceuticals ADIL Stock Holding History

JP Morgan Chase’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-100	Closed	-$4.65K	–	7362
2023 Q4	$4.65K	Buy	+100	New	+$5.48K	﹤0.01%	6566

Other funds holding ADIL

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MCM

Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Headlands Technologies Chicago, Illinois $878M AUM 44.8% 1-Year Est. Return

AWM

Abound Wealth Management Franklin, Tennessee $504M AUM 23.73% 1-Year Est. Return

JP Morgan Chase's ADIL Position: Q1 2024 in Review

JP Morgan Chase sold out of Adial Pharmaceuticals (ADIL) in Q1 2024, closing a stake of 100 shares — an estimated $4.65K sold.

JP Morgan Chase first reported a position in ADIL in Q4 2023 and held it in 1 quarter. The position peaked at $4.65K in Q4 2023. 13 funds tracked by Wall St. Rank hold ADIL as of Q1 2024.

JP Morgan Chase reported no remaining Adial Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
JP Morgan Chase sold 100 Adial Pharmaceuticals shares in Q1 2024, an estimated $4.65K.
JP Morgan Chase first reported a position in Adial Pharmaceuticals in Q4 2023 and held it in 1 quarter.
JP Morgan Chase's Adial Pharmaceuticals position peaked at $4.65K in Q4 2023.
13 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2024.

Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.